Texas MPN Workshop 2021: updates on JAK inhibitors for MPNs

Janus kinase (JAK) inhibitors are becoming an increasingly prominent class of drug in the treatment of myeloproliferative neoplasms (MPNs), in particular for the management of myelofibrosis symptoms. With the FDA approval of ruxolitinib in 2011, followed by the approval of fedratinib in 2019, JAK inhibitors are already established in the myelofibrosis treatment landscape; however, studies investigating novel JAK inhibitors could potentially lead to further approvals. Both pacritinib and momelotinib have demonstrated promising results in the PERSIST-2 trial and the SIMPLIFY-1 and SIMPLIFY-2 trials, and continue to be explored in the ongoing MOMENTUM and PACIFICA trials respectively.

In this podcast, Ruben Mesa, MD, of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, Aaron Gerds, MD, of the Cleveland Clinic, Cleveland, OH, and Abdulraheem Yacoub, MD, MBBS, of The University of Kansas, Westwood, KS, discuss the latest updates on JAK inhibitors for MPNs, as presented at the Texas MPN Workshop: Second Annual Meeting and Workshop 2021.

The post Texas MPN Workshop 2021: updates on JAK inhibitors for MPNs appeared first on VJHemOnc.